Tyra Biosciences, Inc.
TYRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $25 | $24 | $25 | $22 |
| G&A Expenses | $7 | $7 | $7 | $8 |
| SG&A Expenses | $7 | $7 | $7 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $33 | $31 | $32 | $30 |
| Operating Income | -$33 | -$31 | -$32 | -$30 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $3 | $4 | $4 |
| Pre-Tax Income | -$30 | -$28 | -$28 | -$26 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$28 | -$28 | -$26 |
| % Margin | – | – | – | – |
| EPS | -0.5 | -0.47 | -0.47 | -0.43 |
| % Growth | -6.4% | 0% | -9.3% | – |
| EPS Diluted | -0.5 | -0.47 | -0.47 | -0.43 |
| Weighted Avg Shares Out | 60 | 60 | 59 | 59 |
| Weighted Avg Shares Out Dil | 60 | 60 | 59 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $4 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$30 | -$31 | -$32 | -$30 |
| % Margin | – | – | – | – |